Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 7/20 | 0.72 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.72 |
| ▸ | HNF4A | P41235 | 2/20 | 0.72 |
| ▸ | DHFR | P00374 | 1/20 | 0.72 |
| ▸ | CA1 | P00915 | 2/20 | 0.71 |
| ▸ | CA2 | P00918 | 2/20 | 0.71 |
| ▸ | LCK | P06239 | 2/20 | 0.62 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29374831 | 0.90 | ACMSD (0.88) | ACMSDMCL1HNF4ADHFRCA1 | |
| SCHEMBL18224311 | 0.90 | ACMSD (0.88) | ACMSDMCL1HNF4ADHFRCA1 | |
| SCHEMBL29904854 | 0.88 | ACMSD (0.83) | ACMSDMCL1HNF4ADHFRCA1 | |
| SCHEMBL2771723 | 0.88 | ACMSD (0.83) | ACMSDMCL1HNF4ADHFRCA1 | |
| SCHEMBL22206257 | 0.86 | ACMSD (0.80) | ACMSDMCL1HNF4ADHFRCA1 | |
| Methane SCHEMBL28165586 | 0.86 | ACMSD (0.80) | ACMSDMCL1HNF4ADHFRCA1 | |
| SCHEMBL23143193 | 0.84 | ACMSD (1.00) | ACMSDMCL1HNF4ADHFRLCK | |
| SCHEMBL1898000 | 0.84 | ACMSD (0.78) | ACMSDMCL1HNF4ADHFRCA1 | |
| SCHEMBL9273036 | 0.84 | ACMSD (1.00) | ACMSDMCL1HNF4ADHFRLCK | |
| SCHEMBL29759663 | 0.84 | ACMSD (1.00) | ACMSDMCL1HNF4ADHFRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795310-B2 | Methods and reagents for the treatment of metabolic disorders | COMBINATORX, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| EP-1781303-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS | COMBINATORX INC (US) | 2008-07-02 | — | — | EP | disclosed |
| CN-101010083-A | Methods and reagents for the treatment of metabolic disorders | COMBINATORX INC (US) | 2007-08-01 | — | — | CN | disclosed |
| EP-1781303-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS | CombinatoRx, Incorporated (US) | 2007-05-09 | — | — | EP | disclosed |
| CN-1867340-A | Topical use of halosalicylic acid derivatives | AVON PROD INC (US) | 2006-11-22 | — | — | CN | disclosed |
| EP-1694337-A2 | TOPICAL USE OF HALOSALICYLIC ACID DERIVATIVES | AVON PRODUCTS, INC. (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20060069161-A1 | Methods and reagents for the treatment of metabolic disorders | COMBINATORX, INC. (US) | 2006-03-30 | — | — | US | disclosed |
| WO-2006004803-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS | COMBINATORX, INCORPORATED (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2005058230-A2 | TOPICAL USE OF HALOSALICYLIC ACID DERIVATIVES | AVON PRODUCTS, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20050136015-A1 | Topical use of halosalicylic acid derivatives | AVON PRODUCTS, INC. | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050136015-A1 | Topical use of halosalicylic acid derivatives | NACA, TYR, PRKDC | ACMSD 1718/4885MCL1 729/4885HNF4A 3980/4885 |
| US-20060069161-A1 | Methods and reagents for the treatment of metabolic disorders | LIPC, PNLIP, GOT2 | ACMSD 3350/4885MCL1 3721/4885HNF4A 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.